This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• March 2023

Our study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• June 2020

The class 1A aldehyde dehydrogenase (ALDH1A) subfamily of genes encode enzymes that function at the apex of the retinoic acid (RA) signalling pathway. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• January 2015

The aetiology of childhood brain tumours (CBT) is largely unknown. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• January 2015

Introduction Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity of trials for Australian patients with relapsed G2/3 gliomas compared with patients with GBM. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• December 2021

Our results identify a pretreatment tumor microenvironment that predicts response to immune checkpoint blockade, which can be therapeutically attained ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• July 2019

Alison Linda W. Joost Omar McDonnell Wijaya Lesterhuis Elaskalani AM LW WJL OE BSc (Hons), PhD BSc PhD BSc, MSc, PhD Early Career Fellow Postdoctoral Researcher Program Head, Cancer; Chronic and Severe Diseases RFA Deputy Head Senior Research ...

• 1. Telethon Kids Institute
• Projects

Immunotherapies have revolutionized cancer treatment. In particular, immune checkpoint therapy (ICT) leads to durable responses in some patients with some cancers. However, the majority of treated patients do not respond. Understanding immune mechanisms that underlie responsiveness to ICT will help identify predictive biomarkers of response and develop treatments to convert non-responding patients to responding ones. ICT primarily acts at the level of adaptive immunity. The specificity of adaptive immune cells, such as T and B cells, is determined by antigen-specific receptors. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• October 2020

This review explores computational strategies to yield biological insight into the processes involved in the immunotherapeutic response ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• June 2019

Non-Aspergillus molds and non-albicans Candida contributed substantially to pediatric invasive fungal infection in our study ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2019
• April 2019

This study describes the development and molecular characterization of a panel of patient-derived infant leukemia oncogene xenografts and their sensitivity... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• January 2015

We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• February 2012